Skip to main content
Signal8
Launch Terminal

CYPHERPUNK TECHNOLOGIES INC. (CYPH)

Cypherpunk Technologies Inc. is a privacy-focused technology company that combines a digital asset treasury strategy centered on Zcash (ZEC) with the development of novel cancer therapies through its subsidiary. The company's mission is to advance technologies that guarantee privacy for individuals on the internet, with a primary focus on investing in, accelerating the adoption of, and strengthening the ecosystem of Zcash, a privacy-preserving digital currency.

Sector: Pharmaceutical Preparations

Industry: Asset Management

Cypherpunk Technologies Inc. logo

Cypherpunk Technologies Inc.

NASDAQ:CYPHFinancial Services
-9.97%$2.98
AH$3.00+0.67%vs close
Mkt Cap-
Float61.56M
O/S-
Vol
$ Vol
RVOL
Inst Own14.7%
Earnings
Dilution
Cypherpunk Technologies Inc. logoNASDAQ:CYPH$2.98-9.97%
Phase Distribution
11 lead-sponsored trials·0 active·8 completed
Phase 17
Phase 23
Not applicable1
(5 more as collaborator)
Status Overview
Completed8
Stopped2
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

    Paclitaxel, 300mg DKN-01

    Endometrial Cancer, Uterine Cancer +2

    Enrollment
    111
    Start
    Mar 2018
    Primary Completion
    Sep 2020
    Completion
    Jan 2021
    NCT03395080
  • Phase 2
    Terminated

    A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

    DKN-01 300mg, DKN-01 600mg

    Gastric Cancer, Gastric Adenocarcinoma +1

    Enrollment
    247
    Start
    Jul 2020
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT04363801
  • Phase 2
    Completed

    Phase 2 Study of DKN-01 in Colorectal Cancer

    DKN-01, FOLFIRI

    Colorectal Cancer, Colorectal Adenocarcinoma +2

    Enrollment
    188
    Start
    Aug 2022
    Primary Completion
    Jul 2025
    Completion
    Jul 2025
    NCT05480306
  • Phase 1
    Completed

    Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

    TRX518

    Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

    Enrollment
    10
    Start
    Oct 2010
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT01239134
  • Phase 1
    Completed

    A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

    DKN-01

    Multiple Myeloma, Solid Tumors +1

    Enrollment
    32
    Start
    Jan 2012
    Primary Completion
    Dec 2013
    Completion
    Dec 2013
    NCT01457417
  • Phase 1
    Completed

    A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    DKN-01 300 mg, DKN-01 600 mg

    Multiple Myeloma

    Enrollment
    8
    Start
    May 2013
    Primary Completion
    Jul 2015
    Completion
    Jul 2015
    NCT01711671
  • Phase 1
    Completed

    A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

    DKN-01 150 mg, Paclitaxel

    Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction +3

    Enrollment
    151
    Start
    May 2014
    Primary Completion
    Jul 2019
    Completion
    Jan 2021
    NCT02013154
  • Phase 1
    Completed

    Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

    DKN-01, gemcitabine

    Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder +2

    Enrollment
    51
    Start
    Jun 2015
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT02375880
  • Phase 1
    Completed

    Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

    TRX518 monotherapy, TRX518 with gemcitabine

    Solid Tumors

    Enrollment
    109
    Start
    Jan 2016
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT02628574
  • Phase 1
    Terminated

    A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

    TRX518, Cyclophosphamide

    Solid Tumors, Advanced Triple Negative Breast Cancer +3

    Enrollment
    10
    Start
    May 2019
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT03861403
  • Expanded access
    No longer available

    Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

    DKN-01

    Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction +8

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04681248
Search ClinicalTrials.gov for “Cypherpunk Technologies”